Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$121.28 USD
-0.19 (-0.16%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $118.20 -3.08 (-2.54%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NBIX 121.28 -0.19(-0.16%)
Will NBIX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NBIX
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Other News for NBIX
Neurocrine Biosciences Provides Update on ERUDITE? Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)
Resilience Amidst Setbacks: Affirming Buy Rating on Neurocrine Biosciences
Neurocrine ending development of luvadaxistat amid failed study
Neurocrine's luvadaxistat did not meet primary endpoint in schizophrenia trial